Skip to content

Net Income at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$330.96M+174%
Biogen logo
BiogenBIIB
$319.5M+32.8%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$197.9M+2,405%
Insmed logo
InsmedINSM
-$163.56M+36.3%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
-$120.85M-4.8%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
-$42.41M-97.0%

Other financials

Income statement

See full
Revenue$2.0M-40.6%
Operating income-$57.3M-43.1%
EPS (diluted)-$0.52+11.9%

Balance sheet

See full
Cash & equivalents$297.1M+41.1%
Total debt$20.7M-12.5%
Total equity$374.1M+27.1%
Total assets$422.9M+23.0%

Cash flow

See full
Operating cash flow-$47.2M-48.3%
CapEx$165.0K+31.0%
Free cash flow-$47.4M-48.2%

Valuation

See full
Market cap$910.66M+145%
Enterprise value$634.23M+244%
P/S112.5×-10.3×

Profitability

See full
Operating margin-1,315.2%-4,060pp
Net margin-1,062.3%-251,151pp
FCF margin-1,247.7%-9,569pp

Returns & leverage

See full
Return on equity-57.4%+2.2pp
Debt / equity0.1×0.0×
Current ratio13.1×+2.2×

Where this comes from

Reported directly by Solid Biosciences Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProfitLoss.

The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Solid Biosciences Inc.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Solid Biosciences Inc.'s net income?
Solid Biosciences Inc. (SLDB) reported net income of -$56.74M in Q1 2026.
How has Solid Biosciences Inc.'s net income changed year-over-year?
Solid Biosciences Inc.'s net income decreased by 44.4% year-over-year, from -$39.28M to -$56.74M.
What is the long-term trend for Solid Biosciences Inc.'s net income?
Over 4 years (2021 to 2025), Solid Biosciences Inc.'s net income has grown at a 24.7% compound annual growth rate (CAGR), from -$72.19M to -$174.33M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.